GFS Advisors LLC Acquires New Stake in Bristol-Myers Squibb Company (NYSE:BMY)
GFS Advisors LLC bought a new stake in Bristol-Myers Squibb Company (NYSE:BMY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,034 shares of the biopharmaceutical company’s stock, valued at approximately $274,000.
A number of other large investors have also added to or reduced their stakes in BMY. Willingdon Wealth Management boosted its stake in shares of Bristol-Myers Squibb by 83.7% in the first quarter. Willingdon Wealth Management now owns 121,618 shares of the biopharmaceutical company’s stock worth $6,614,000 after buying an additional 55,420 shares during the period. Usca Ria LLC boosted its stake in shares of Bristol-Myers Squibb by 21.7% in the first quarter. Usca Ria LLC now owns 49,523 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 8,814 shares during the period. Biondo Investment Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 16.4% in the first quarter. Biondo Investment Advisors LLC now owns 124,367 shares of the biopharmaceutical company’s stock worth $9,147,000 after buying an additional 17,539 shares during the period. One Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 411.2% in the first quarter. One Capital Management LLC now owns 23,061 shares of the biopharmaceutical company’s stock worth $1,254,000 after buying an additional 18,550 shares during the period. Finally, Great West Life Assurance Co. Can boosted its stake in shares of Bristol-Myers Squibb by 8.7% in the first quarter. Great West Life Assurance Co. Can now owns 1,377,631 shares of the biopharmaceutical company’s stock worth $74,889,000 after buying an additional 110,368 shares during the period. 69.56% of the stock is owned by institutional investors and hedge funds.
Bristol-Myers Squibb Company (BMY) traded up 0.81% on Friday, reaching $55.95. The company’s stock had a trading volume of 4,150,120 shares. The company has a market capitalization of $91.75 billion, a PE ratio of 20.43 and a beta of 1.17. The firm has a 50-day moving average of $55.55 and a 200-day moving average of $54.50. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $75.62. Bristol-Myers Squibb also was the target of some unusual options trading activity on Thursday. Traders acquired 781 put options on the stock. This is an increase of approximately 117% compared to the typical volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 EPS. The business’s revenue for the quarter was up 5.6% on a year-over-year basis. Analysts predict that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were paid a $0.39 dividend. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.79%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.
A number of analysts recently commented on BMY shares. Vetr upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target on the stock in a report on Monday, June 5th. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. BidaskClub upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Robert W. Baird began coverage on Bristol-Myers Squibb in a research note on Tuesday, April 25th. They set an “outperform” rating on the stock. Finally, Deutsche Bank AG set a $55.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, July 17th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $63.32.
In related news, Director Theodore R. Samuels II acquired 6,000 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.